ĐẶC ĐIỂM SINH HỌC VÀ KẾT QUẢ ĐIỀU TRỊ Ở BỆNH NHÂN BẠCH CẦU CẤP THỂ HỖN HỢP (MPAL): NGHIÊN CỨU HỒI CỨU TẠI BỆNH VIỆN CHỢ RẪY
Background: Mixed Phenotype Acute Leukemia (MPAL) is a rare type of acute leukemia characterized by the expression of markers from more than one hematopoietic lineage. Because of its biological heterogeneity, the diagnosis of MPAL requires a combination of morphological examination, immunophenotyping, and cytogenetic analysis according to current diagnostic criteria. MPAL is associated with an aggressive clinical course and poor prognosis, and the optimal treatment strategy has not yet been established.Objective: This study aimed to describe the biological characteristics and evaluate the treatment outcomes of patients with MPAL treated at Cho Ray Hospital.Subjects and methods: We conducted a retrospective cohort study of 29 patients with de novo MPAL diagnosed at Cho Ray Hospital between April 2016 and June 2026. The diagnosis was based on the European Group for the Immunological Characterization of Leukemias (EGIL) criteria and the 2016 and 2022 World Health Organization (WHO) classifications. Clinical features, hematological findings, immunophenotypic characteristics, cytogenetic abnormalities, treatment, and overall survival (OS) were analyzed.Results: Among the 29 patients, the myeloid/B-lymphoid (My/B) subtype was the most common (19 patients, 65.5%), followed by myeloid/T-lymphoid (My/T) (8 patients, 27.6%) and B/T-lymphoid (2 patients, 6.9%). No patient had the B/T/myeloid subtype. The median age was 49 years (range, 17–79 years), and the male-to-female ratio was 1.07:1. Based on the French–American–British (FAB) classification, 55.2% of patients had AML-like morphology, 17.2% had ALL-like morphology, and 27.6% were classified as acute undifferentiated leukemia (AUL). Cytogenetic abnormalities were identified in 12 patients (41.4%), including the Philadelphia chromosome [t(9;22)] in four patients (13.8%). Immunophenotyping confirmed the diagnosis of MPAL, with the My/B and My/T subtypes showing markers of both myeloid and the corresponding lymphoid lineage. Twelve patients received disease-specific treatment, most commonly Hyper-CVAD–based chemotherapy. The median OS for the entire cohort was 59 days. Median OS was 27 days in untreated patients and 148 days in treated patients (p < 0.001).Conclusion: MPAL is a rare and biologically heterogeneous acute leukemia, with the My/B subtype being the most common. Diagnosis requires immunophenotyping combined with cytogenetic analysis. Longer overall survival was observed in patients who received disease-specific treatment compared to those untreated, though overall prognosis remains poor. Prospective studies with larger cohorts are needed to control for selection bias and better define optimal treatment strategies.
Authors
- Phan Cong Hoang
- Thi Thuy Dung Nguyen (ORCID: https://orcid.org/0000-0002-5050-574X)
- Nguyễn Thị Lan Hương (ORCID: https://orcid.org/0009-0006-3545-8574)
- Hoàng Quỳnh An Dương
- Hồng Phước Mạc
- Ngọc Quế Anh Nguyễn
- Thị Minh Hằng Trần
- Dương Bích Trâm Huỳnh
- Dương Trường Dung Trần
Publication Details
- Journal
- Journal of Clinical Medicine Bach Mai Hospital
- Published
- 2026-11-21
- DOI
- https://doi.org/10.52322/jocmbmh.156.0306
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00